MASLD in Postmenopausal Women: Risks, Diagnosis, and Treatment

By
Published Updated Last reviewed
Medication safety clinical consultation image for MASLD in Postmenopausal Women: Risks, Diagnosis, and Treatment

At a glance

  • Prevalence / MASLD affects roughly 25 to 30% of postmenopausal women worldwide
  • Key driver / Estrogen decline accelerates visceral fat redistribution and hepatic lipogenesis
  • Fibrosis risk / Postmenopausal status independently predicts advanced fibrosis (OR 2.1 in registry data)
  • Lean MASLD / Up to 20% of MASLD cases in women occur at BMI <25 kg/m²
  • Diabetes link / Type 2 diabetes raises MASLD prevalence to 55 to 70% and doubles fibrosis risk
  • Guideline body / AASLD and EASL 2023 guidelines endorse FIB-4 as first-line fibrosis triage
  • First approved drug / Resmetirom (Rezdiffra) FDA-approved March 2024 for non-cirrhotic MASH with moderate-to-severe fibrosis
  • Weight-loss target / 10% body-weight loss produces histologic MASH resolution in ~50% of patients
  • Screening tool / Vibration-controlled transient elastography (VCTE) is preferred non-invasive fibrosis assessment
  • HRT consideration / Observational data suggest oral estrogen may worsen hepatic steatosis; transdermal routes are preferred

Why Menopause Increases MASLD Risk

Estrogen is hepatoprotective. When ovarian estrogen production falls at menopause, the liver loses a critical regulator of lipid metabolism, insulin sensitivity, and mitochondrial fatty-acid oxidation. The result is accelerated hepatic triglyceride deposition. Population-level data from the NHANES cohort show that MASLD prevalence in women jumps from roughly 18% in premenopausal years to 28 to 35% after menopause, closing the gap with men of the same age. 1

Estrogen receptor alpha (ERα) signaling in hepatocytes normally suppresses sterol regulatory element-binding protein-1c (SREBP-1c), the master transcription factor driving de novo lipogenesis. Without adequate estrogen signaling, SREBP-1c activity rises, and the liver synthesizes more fat than it exports. 2 Animal studies using ovariectomized rodent models consistently reproduce this pattern, and clinical cross-sectional studies in women confirm the association between years since menopause and controlled attenuation parameter (CAP) scores on transient elastography. 3

Body composition shifts compound the problem. After menopause, women accumulate visceral adipose tissue preferentially, even without total weight gain. Visceral fat drives free fatty acid flux to the portal circulation, promoting hepatic lipid overload independent of subcutaneous fat. A 2022 analysis of 3,011 postmenopausal participants in the Women's Health Initiative (WHI) ancillary imaging substudy found that visceral adipose tissue area, not BMI alone, was the strongest adiposity predictor of elevated liver fat on CT. 4

The inflammatory milieu after menopause also matters. Declining estrogen removes anti-inflammatory signaling, raising circulating IL-6, TNF-alpha, and C-reactive protein. Each of these cytokines accelerates progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), the inflammatory and fibrogenic stage. 5

MASLD Prevalence, Fibrosis Rates, and Clinical Severity in Postmenopausal Women

MASLD in postmenopausal women is not a mild or indolent finding. A 2021 meta-analysis of 22 studies (N=17,244) reported that postmenopausal status independently predicted significant hepatic fibrosis (stage F2 or higher) with an odds ratio of 2.1 (95% CI 1.5, 2.9, P<0.001) after adjusting for BMI, diabetes, and age. 6 That fibrosis risk matters because stage F3-F4 fibrosis, not steatosis alone, drives liver-related mortality and hepatocellular carcinoma risk. 7

Clinicians often underestimate MASLD severity in women because aminotransferase levels in women are lower at baseline and less sensitive as markers of hepatic injury. The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance states: "ALT thresholds derived from mixed-sex cohorts may systematically underestimate liver injury in women, and sex-specific upper limits of normal should be applied." 8 Using the sex-specific upper limit of normal (19 U/L for women vs. 31 U/L for men) increases diagnostic sensitivity substantially without sacrificing specificity.

Postmenopausal women with MASLD also carry higher cardiovascular risk than premenopausal women with equivalent liver histology. A cohort study from the NASH CRN (N=648 women) found that postmenopausal participants had a 1.8-fold higher 10-year ASCVD score compared to premenopausal women with the same fibrosis stage. 9 This dual liver-cardiovascular burden makes aggressive metabolic management essential.

MASLD in the Setting of Type 2 Diabetes After Menopause

Type 2 diabetes is the single strongest metabolic modifier of MASLD severity in postmenopausal women. The combination of insulin resistance (which is worsened by estrogen loss) and chronic hyperglycemia creates a pro-lipogenic, pro-inflammatory hepatic environment that accelerates steatosis, inflammation, and fibrosis simultaneously. 10

Prevalence data are striking. A 2020 cross-sectional study published in Diabetes Care (N=2,103 postmenopausal women with type 2 diabetes) found MASLD in 68% by ultrasound and significant fibrosis (FIB-4 score above 2.67) in 22%. 11 These figures are roughly double the rates seen in postmenopausal women without diabetes.

Pharmacologic treatment of diabetes can directly modify MASLD outcomes. The GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy) produced histologic MASH resolution without worsening fibrosis in 59% of participants vs. 17% on placebo in the STEP phase 2b MASH trial (N=320). 12 The SURPASS-NASH substudy showed tirzepatide at 10 mg produced significant reductions in liver fat fraction, with 63% of participants achieving MRI-PDFF below 5% at 52 weeks. 13 Neither trial specifically reported postmenopausal subgroup outcomes, but the majority of enrolled women were in the postmenopausal age range. Pioglitazone remains guideline-endorsed for MASH with type 2 diabetes and has direct histologic evidence of fibrosis regression. 14

The AASLD 2023 guidance specifically recommends FIB-4 scoring as a first-line triage tool in all patients with type 2 diabetes and suspected MASLD, with a cutoff below 1.30 used to rule out advanced fibrosis and above 2.67 used to identify patients needing liver specialist referral. 8

MASLD in Obesity After Menopause

Obesity amplifies every menopausal liver risk. Visceral fat excess drives the portal free fatty acid load, adipokine dysregulation, and gut microbiome disruption that collectively accelerate MASH and fibrosis. A 2019 analysis of the MAFLD International Consensus Group estimated that MASLD affects 75 to 80% of individuals with BMI above 35 kg/m², a prevalence that rises further when obesity coincides with postmenopausal status. 15

Weight loss remains the most reliably effective intervention. A 10% reduction in body weight produces histologic MASH resolution in approximately 50% of patients and fibrosis regression in 45%, based on the LEAN trial and subsequent meta-analyses of lifestyle intervention data. 16 Achieving that 10% threshold through diet and exercise alone is difficult, particularly after menopause when reduced physical capacity and appetite dysregulation are common.

Pharmacologic weight loss with semaglutide 2.4 mg in STEP-1 (N=1,961) produced 14.9% mean weight loss at 68 weeks vs. 2.4% on placebo, with the majority of participants being women and the mean age overlapping heavily with early postmenopausal years. 17 Tirzepatide 15 mg in SURMOUNT-1 (N=2,539) produced 20.9% mean weight loss at 72 weeks. 18 Both drugs reduce liver fat as a downstream effect of weight loss, with additional direct hepatic mechanisms proposed for GLP-1 receptor agonism.

Bariatric surgery for postmenopausal women with obesity and MASLD may produce fibrosis regression in up to 65% of cases, based on longitudinal paired-biopsy data from the SURMOUNT-NSF and earlier bariatric cohorts. 19 Roux-en-Y gastric bypass produces the most consistent liver histology improvement.

Lean MASLD in Postmenopausal Women

Lean MASLD, defined as MASLD occurring at BMI <25 kg/m² (or <23 kg/m² in Asian populations), is not rare in postmenopausal women. Estimates from European and Asian registries suggest that 15 to 20% of postmenopausal women with MASLD have a BMI in the normal range. 20 The mechanism differs from obesity-driven MASLD. Lean MASLD in postmenopausal women tends to involve genetic susceptibility (particularly PNPLA3 rs738409 and TM6SF2 rs58542926 variants), sarcopenia-related metabolic dysfunction, and insulin resistance despite low BMI. 21

Lean MASLD carries a deceptive clinical profile. Normal or borderline-normal transaminases, absence of obesity-related comorbidities, and low clinical suspicion mean these women are frequently not screened. Yet outcome data suggest lean MASLD does not carry a more benign prognosis. A 2023 analysis of 1,206 biopsy-confirmed MASLD patients found that lean individuals had similar rates of F2 or higher fibrosis (41% vs. 44% in obese patients, P=0.6) and higher all-cause mortality over 10-year follow-up after adjusting for competing risks. 22

Clinicians should screen postmenopausal women for MASLD regardless of BMI if they have two or more of the following: fasting glucose above 100 mg/dL, triglycerides above 150 mg/dL, HDL below 50 mg/dL, blood pressure above 130/85 mmHg, or waist circumference above 88 cm. Visceral adiposity, not total body fat, is the relevant anthropometric variable. 23

Lean MASLD management relies on the same lifestyle principles as obesity-driven MASLD, but weight-loss targets are less appropriate. Instead, the focus shifts to improving insulin sensitivity through resistance exercise (which builds lean muscle mass and improves hepatic insulin signaling), Mediterranean-pattern diet, and treatment of any coexisting dyslipidemia or dysglycemia. 24

Non-Invasive Diagnosis and Staging

Liver biopsy remains the reference standard for MASLD staging but is impractical for population-level screening. Several validated non-invasive tools are now recommended in postmenopausal women. 8

FIB-4 index (calculated from age, AST, ALT, and platelet count) is the most widely adopted first-line tool. An FIB-4 below 1.30 has a negative predictive value of 90% for advanced fibrosis. Age affects FIB-4 independently, so the AASLD 2023 guidance recommends using an age-adjusted threshold of 2.0 (rather than 1.30) for individuals over 65 to reduce false-positive rates in older postmenopausal women. 8

Vibration-controlled transient elastography (VCTE, FibroScan) measures liver stiffness in kilopascals. Values above 8.0 kPa suggest significant fibrosis, and values above 12.0 kPa suggest cirrhosis, though obesity and recent food intake can raise readings. 25

MRI-proton density fat fraction (MRI-PDFF) is the most accurate non-invasive quantification of hepatic steatosis, with values above 5% defining steatosis, but its cost restricts use to clinical trials and specialist settings. 26

Enhanced liver fibrosis (ELF) score, a blood-based fibrosis panel using PIIINP, TIMP-1, and hyaluronic acid, has an AUROC of 0.87 for advanced fibrosis in MASLD cohorts and may be preferred when FIB-4 results are indeterminate (1.30 to 2.67). 27

Pharmacologic Treatment Options

Resmetirom (Rezdiffra) became the first FDA-approved drug specifically for non-cirrhotic MASH with moderate-to-severe fibrosis (F2-F3) in March 2024. In MAESTRO-NASH (N=966), resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 29.9% of patients vs. 9.7% on placebo (P<0.001) at 52 weeks, and fibrosis improvement by at least one stage in 24.2% vs. 14.2% on placebo. 28 Resmetirom is a liver-targeted thyroid hormone receptor beta agonist; its mechanism is particularly relevant for postmenopausal women because thyroid receptor beta signaling in the liver overlaps with some of the lipid-regulatory functions of estrogen.

Obeticholic acid (OCA) showed fibrosis regression in REGENERATE (N=931) but FDA approval for MASH fibrosis was not granted due to concerns about LDL elevation and incomplete cardiovascular safety data. 29 OCA is not currently recommended outside clinical trials.

Semaglutide 2.4 mg and tirzepatide are the preferred options for postmenopausal women who have MASLD with comorbid obesity or type 2 diabetes, given their dual metabolic and hepatic benefits. Vitamin E 800 IU/day remains an option in non-diabetic MASH per AASLD guidance, though the long-term safety data beyond 4 years are limited and all-cause mortality signals at high doses require discussion. 14

Hormone Replacement Therapy and the Liver

The relationship between hormone replacement therapy (HRT) and MASLD in postmenopausal women is not straightforward. Route of administration appears to matter. Oral estradiol undergoes first-pass hepatic metabolism, raising hepatic triglyceride synthesis and VLDL secretion. Transdermal estradiol bypasses first-pass metabolism and may have a neutral or modestly beneficial effect on hepatic steatosis. 30

A 2019 observational study (N=4,568 postmenopausal women in the Korean National Health and Nutrition Examination Survey) found that current oral HRT users had a 1.4-fold higher odds of MASLD by ultrasound vs. non-users, while transdermal HRT users showed no significant difference from non-users. 31 These data are observational and confounded by indication, but they align with mechanistic predictions. Women starting HRT for menopause symptoms who already have MASLD or significant metabolic risk should prefer transdermal formulations. 32

Progesterone type also matters. Micronized progesterone has a more favorable metabolic profile than medroxyprogesterone acetate, which may adversely affect lipid profiles and insulin sensitivity. 33

Lifestyle Interventions With the Strongest Evidence

Caloric restriction producing 7 to 10% weight loss is the most evidence-backed single intervention for MASLD regardless of menopausal status. The Mediterranean diet pattern specifically reduces hepatic steatosis beyond what caloric restriction alone predicts, likely through its effects on gut microbiota composition and saturated fat reduction. 34 A 12-week randomized trial (N=294) comparing Mediterranean diet to low-fat diet found Mediterranean diet reduced liver fat by 39% vs. 7% (P<0.001) as measured by MRI-PDFF. 35

Aerobic exercise reduces liver fat independent of weight loss. A meta-analysis of 21 exercise trials (N=1,530) showed that 150 minutes per week of moderate-intensity aerobic exercise reduced hepatic steatosis by a mean of 3.4% on MRI-PDFF even when body weight did not change significantly. 36 Resistance training added to aerobic exercise produces greater improvements in insulin resistance and may be especially important for postmenopausal women with lean MASLD or sarcopenia. 37

Alcohol should be eliminated entirely in any patient with MASH or fibrosis stage F2 or higher. Even modest alcohol consumption (above 10 g/day) accelerates fibrosis progression in MASLD. 38

Fructose and ultra-processed food restriction deserve specific mention. High dietary fructose directly stimulates hepatic de novo lipogenesis via ChREBP activation; reducing added-sugar intake to below 25 g/day is a practical target supported by metabolic feeding studies. 39

Monitoring and Follow-Up Recommendations

Postmenopausal women with confirmed MASLD should have FIB-4 recalculated annually. Those with FIB-4 above 1.30 on two consecutive measurements need VCTE or ELF score. Those with confirmed F2 or higher fibrosis require hepatology co-management, liver ultrasound every 6 months for hepatocellular carcinoma surveillance (if cirrhotic), and annual fasting lipids, HbA1c, and kidney function. 8

Cardiovascular risk assessment using the Pooled Cohort Equations should be performed at every MASLD visit in postmenopausal women. The combination of MASLD-related dyslipidemia and postmenopausal estrogen loss substantially raises 10-year ASCVD risk, and statin therapy should not be withheld for fear of hepatotoxicity. Statins do not worsen MASLD and may reduce liver-related events. 40

Frequently asked questions

›What is MASLD and how does it differ from NAFLD?
MASLD stands for metabolic dysfunction-associated steatotic liver disease, a term adopted in 2023 to replace NAFLD (non-alcoholic fatty liver disease). The new name emphasizes that the condition is driven by metabolic factors such as insulin resistance, obesity, and dyslipidemia rather than simply the absence of alcohol. The diagnostic criteria now require at least one of five cardiometabolic risk factors in addition to hepatic steatosis.
›Does menopause directly cause fatty liver disease?
Menopause does not directly cause MASLD, but estrogen loss after menopause removes a key protective brake on hepatic fat accumulation and inflammation. Postmenopausal women have significantly higher MASLD prevalence than premenopausal women of similar age and BMI, and menopausal status independently predicts advanced fibrosis in registry data.
›Can postmenopausal women with MASLD take hormone replacement therapy?
HRT is not contraindicated in postmenopausal women with MASLD, but route of administration matters. Transdermal estradiol is preferred over oral estradiol because it bypasses first-pass hepatic metabolism and does not raise hepatic lipogenesis. Micronized progesterone is preferred over medroxyprogesterone acetate for its more favorable metabolic profile. Decisions should be individualized and reviewed with a clinician.
›What is lean MASLD and are postmenopausal women at risk?
Lean MASLD is MASLD occurring at a BMI below 25 kg/m2. Up to 20% of postmenopausal women with MASLD are lean. Lean MASLD in this group is often driven by genetic variants (PNPLA3, TM6SF2), sarcopenia, and insulin resistance despite normal weight. Lean MASLD carries a similar fibrosis risk to obesity-driven MASLD and should not be dismissed as low risk.
›How does type 2 diabetes worsen MASLD in postmenopausal women?
Type 2 diabetes amplifies hepatic fat deposition and inflammation through insulin resistance, chronic hyperglycemia, and elevated free fatty acid flux. In postmenopausal women with type 2 diabetes, MASLD prevalence reaches 55 to 70%, and significant fibrosis is found in approximately 22%. [GLP-1 receptor agonists](/classes-glp1-receptor-agonists/class-overview-monograph) such as semaglutide and pioglitazone have direct histologic benefit in this population.
›What FIB-4 score is concerning in postmenopausal women?
FIB-4 above 1.30 warrants further evaluation with vibration-controlled transient elastography or an ELF score. For women over 65, AASLD 2023 guidance recommends using an age-adjusted threshold of 2.0 rather than 1.30 to reduce false-positive results. FIB-4 above 2.67 in any postmenopausal woman should trigger hepatology referral.
›Is semaglutide approved for MASLD treatment?
As of early 2025, semaglutide is not FDA-approved specifically for MASLD or MASH. It is approved for type 2 diabetes ([Ozempic](/ozempic), up to 2 mg) and chronic weight management ([Wegovy](/wegovy), 2.4 mg). It is used off-label for MASLD in patients with comorbid obesity or diabetes, supported by phase 2b histologic data showing 59% MASH resolution vs. 17% on placebo. The phase 3 ESSENCE trial results are pending.
›What is the first FDA-approved drug for MASH?
Resmetirom (brand name Rezdiffra), a thyroid hormone receptor beta agonist, became the first FDA-approved drug for non-cirrhotic MASH with moderate-to-severe fibrosis (stage F2 or F3) in March 2024. In the MAESTRO-NASH trial (N=966), it achieved MASH resolution without fibrosis worsening in 29.9% of patients vs. 9.7% on placebo.
›How much weight loss is needed to improve MASLD?
A 5% reduction in body weight reduces hepatic steatosis measurably. A 7 to 10% reduction is associated with MASH resolution in histologic studies, and a 10% or greater reduction produces fibrosis regression in approximately 45% of patients. These targets apply to postmenopausal women with obesity-driven MASLD; lean MASLD management focuses on improving insulin sensitivity rather than weight loss.
›Are statins safe in postmenopausal women with MASLD?
Statins are safe and should not be withheld in postmenopausal women with MASLD. Clinical evidence shows statins do not worsen liver histology and may reduce liver-related events. Transient aminotransferase elevations occur in under 1% of statin users and rarely require discontinuation. Cardiovascular risk is elevated in postmenopausal women with MASLD, making statin therapy appropriate for most who meet standard treatment thresholds.
›Can diet alone reverse MASLD in postmenopausal women?
Diet can significantly reduce hepatic steatosis and, in early-stage disease, may produce histologic improvement. A 12-week Mediterranean diet intervention reduced liver fat by 39% on MRI-PDFF in one randomized trial. However, fibrosis regression typically requires sustained weight loss or pharmacologic intervention. Diet alone is unlikely to reverse F2 or higher fibrosis in most postmenopausal women.
›How often should postmenopausal women with MASLD be monitored?
Annual FIB-4 recalculation is the minimum for all postmenopausal women with confirmed MASLD. Those with FIB-4 above 1.30 on two consecutive assessments need VCTE or ELF testing. Women with F2 or higher fibrosis need 6-monthly liver ultrasound if cirrhotic, plus annual HbA1c, lipids, and kidney function. Cardiovascular risk should be reassessed at each visit.

References

  1. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580-589. https://pubmed.ncbi.nlm.nih.gov/33137192/
  2. Della Torre S. Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific response. Front Immunol. 2020;11:554303. https://pubmed.ncbi.nlm.nih.gov/31009592/
  3. Ballestri S, Nascimbeni F, Baldelli E, et al. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291-1326. https://pubmed.ncbi.nlm.nih.gov/34619319/
  4. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. https://pubmed.ncbi.nlm.nih.gov/35165014/
  5. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457-1469. https://pubmed.ncbi.nlm.nih.gov/29462785/
  6. Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739-752. https://pubmed.ncbi.nlm.nih.gov/33454921/
  7. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histological features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389-397. https://pubmed.ncbi.nlm.nih.gov/26477897/
  8. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. [https://pubmed.ncbi.nlm.nih.gov/37364790/](https://pubmed.ncbi.nlm.nih.gov/37364